Granules India gets USFDA'S nod forVenlafaxine ER capsules
The approved drug is bioequivalent to the reference listed drug product (RLD), Effexor XR Extended-Release Capsules of Upjohn US 2 LLC.20-05-2023
20-05-2023
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited Received ANDA Approval for Venlafaxine ER Capsules19-05-2023
Buy Granules India; target of Rs 350: Sharekhan
Sharekhan is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 350 in its research report dated May 17, 2023.18-05-2023
GRANULES INDIA LTD.-$ - 532482 - Fixed The Date Of The Book Closure For The Purpose Of The Annual General Meeting From August 04, 2023 To August 10, 2023.
Fixed the date of the book closure for the purpose of the Annual General Meeting from August 04, 2023 to August 10, 2023.17-05-2023
GRANULES INDIA LTD.-$ - 532482 - Fixed The Record Date For The Purpose Of Payment Of The Final Dividend For The FY 2022-23 As August 03, 2023.
Fixed the record date for the purpose of payment of the final dividend for the FY 2022-23 as August 03, 2023.17-05-2023
Granules India's Q4 net up 8% at 120 crore
The revenue increased 16 per cent at 1,195 crore as against 1,030 crore in the year ago period.16-05-2023
GRANULES INDIA LTD.-$ - 532482 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 201516-05-2023
Granules India Results Earnings Call for Q4FY23
Conference Call with Granules India Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.16-05-2023
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the Earnings Conference call for Q4 and financial year ended on March 31, 2023.16-05-2023
Q4FY23 Quarterly Result Announced for Granules India Ltd.
Pharmaceuticals company Granules India announced Q4FY23 results: Revenue from operations of Q4FY23 stood at Rs 11,955 million, a growth of 16% YoY, primarily driven by higher sales in key geographies, including the US and Europe. Revenue share from the USA increased to 54% in Q4FY23 as compared to 48% YoY. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and finished dosages contribute 31%, 18%, and 51% of revenue from operations respectively for Q4FY23. RoCE increased to 21.1% as compared to 19.3% YoY Net debt stood at Rs 7,671 million and Net debt to EBITDA at 0.84x Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India said, “We have grown in terms of revenues year on year as well as sequential quarter despite the price erosion challenges in our key geographies including the US. Our Cash flow from operations has improved significantly this year as compared to FY22. This shows the strength of our business and will also help us fund our green initiatives in the coming quarters and years. We are moving towards a more sustainability-driven approach in the future and all our efforts and plans are geared towards that.” Result PDF16-05-2023